Application No. 08/816,011 Attorney Docket: 01142.0122

IN THE CLAIMS:

Please amend claims 4-13, 16, 19, 24-26, 29-32, 38, and 39 as follows:

Jul 6'

- 4. (Amended) The potassium channel of Claim 3 wherein the pore-forming domain comprises SEQ ID NO:57, wherein
 - (i) X at positions 1, 4, and 5 are T or S;
 - (ii) X at position 6 is I or V; and
 - (iii) X at position 8 is V, L, Y, F, M, or I.
 - 5. (Amended) The potassium channel of Claim 4 where X at position 8 is L or I.
- 6. (Amended) The potassium channel of Claim 1, wherein at least one pore-forming domain is positioned proximal to an exterior portion of a cell membrane.
- 7. (Amended) The potassium channel of Claim 5 further comprising SEQ ID NO:58 downstream of said first pore-forming domain.
- 8. (Amended) The potassium channel of Claim 7 wherein SEQ ID NO:58 is positioned about 12-25 amino acids downstream of said first pore-forming domain.
- 9. (Amended) The potassium channel of Claim 8 wherein SEQ ID NO:58 is positioned within the second transmembrane domain.



FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com 10. (Amended) The potassium channel of Claim 8 wherein SEQ ID NO:58 is positioned beginning about 16 amino acids downstream of said first pore-forming domain.

JU)

) 11. (Amended) The potassium channel of Claim 8, wherein a second peptide comprising SEQ ID NO 58 is located within said second pore-forming region.

E3

12. (Amended) The potassium channel of Claim 8, wherein X at positions 1-4 are the amino acids YALL

13. (Amended) The potassium channel of Claim 12 wherein SEQ ID NO:58 is the amino acids YALLGIP.

E4

16. (Amended) The potassium channel of Claim 1, characterized in that it is derived from invertebrates.

E5

19. (Amended) The petassium channel of Claim 1, characterized in that it is derived from vertebrates.

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

24. (Amended) An isolated nucleotide sequence comprising

(i) the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:36;

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400

www.finnegan.com

(ii) a nucleotide sequence that hybridizes to said sequence of SEQ ID NO:1 or SEQ

ID NO:36;

(iii) a nucleotide sequence that is degenerate to the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:36; or

(iv) a functional derivative of the nucleotide sequence of SEQ ID NO:1 or SEQ ID

NO:36.

- 25. (Amended) An isolated nucleotide sequence comprising
- (i) the nucleotide sequence of SEQ ID NO:46;
- (ii) a nucleolide sequence that hybridizes to said sequence of SEQ ID NO:46;
- (iii) a nucleotide sequence that is degenerate to the nucleotide sequence of SEQ ID

NO:46; or

- (iv) a functional derivative of the nucleotide sequence of SEQ ID NO:46.
- 26. (Amended) An isolated nucleotide sequence comprising
- (i) the nucleotide sequence of SEQ ID NO:51, SEQ ID NO:52, or SEQ ID NO:53;
- (ii) a nucleotide sequence that hybridizés to said sequence of SEQ ID NO:51, SEQ ID

NO:52, or SEQ ID NO:53;

- (iii) a nucleotide sequence that is degenerate to the nucleotide sequence of SEQ ID NO:51, SEQ ID NO:52, or SEQ ID NO:53; or
- (iv) a functional derivative of the nucleotide sequence of SEQ ID NO:52, SEQ ID NO:52, or SEQ ID NO:53.

Eb

FINNEGAN HENDERSON FARABOW GARRETT& DUNNERLLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com ly.

- 29. (Amended) An expression vector capable of expressing the potassium channel encoded by the nucleotide sequence of Claim 24 in a cell membrane of a yeast cell.
 - 30. (Amended) A transformed yeast cell comprising the expression vector of Claim

July 1

27.

31. (Amended) A method of assaying substances to determine effects on cell growth, the method comprising the steps of:

- a) preparing cultures of yeast cells in a medium adequate to support growth of potassium-dependent mutant strains expressing the nucleotide sequence of Claim 22;
- b) contacting said substance to a portion of said yeast cells thereafter permitting sufficient time for continued growth, if any, of the portion of yeast cells so contacted as well as the portion not contacted with said substance;
- c) identifying zones of growth around the substances, wherein the level of growth indicates whether or not activity of the heterologous potassium channel has been modulated as compared to yeast cells not contacted with said substances.
- 32. (Amended) The method of Claim 31 wherein said yeast cells comprise the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:36, SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, or SEQ ID NO:53.

FINNEGAN HENDERSON FARABOW GARRETT& DUNNER LLP

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com